Output

Meetings
During the year, the Child and Adolescent Neuropsychopharmacology Network organises meetings for its members (also at the annual ECNP Congress).

Research projects

  • conect4children (Collaborative Network for European Clinical Trials for Children)
    European Union’s Horizon 2020 research and innovation programme and EFPIA, Grant Agreement no. 777389.

  • PERS (Pediatric European Risperidone Studies)

  • STOP (Suicidality: Treatment Occurring in Paediatrics)

  • ADDUCE (Attention-Deficit Hyperactivity Disorder Drugs Use Chronic Effects)
    European Union’s Seventh Framework Programme for research, technological development and demonstration, Grant Agreement no. 603016.

  • TACTICS (Translational Adolescent and Childhood Therapeutic Interventions in Compulsive Syndromes)
    European Community's Seventh Framework Programme (FP7/2007-2013), Grant Agreement no. 260576.

  • Aggressotype (Aggression subtyping for improved insight and treatment innovation in psychiatric disorders)
    European Union’s Seventh Framework Programme for research, technological development and demonstration, Grant Agreement no. 602805.

  • MATRICS (Multidisciplinary Approaches to Translational Research In Conduct Syndromes)
    European Union’s Seventh Framework Programme for research, technological development and demonstration, Grant Agreement no. 603016.

Targeted Network Meetings

  • ‘Emotional lability in mood and behaviour as potential target for pharmacological intervention’ (6 September 2017, after the 30th ECNP Congress, Paris, France).
  • Targeted Network Meeting, 4-5 October 2013, Barcelona, Spain.

ECNP School of Child and Adolescent Neuropsychopharmacology
The ECNP School of Child and Adolescent Neuropsychopharmacology has been established to encourage and spread excellence in clinical neuropsychopharmacology among child and adolescent psychiatrists. It is held yearly in Venice, Italy.

ECAPN (European Child & Adolescent Psychopharmacology Network)
ECAPN is an initiative of the ECNP Child & Adolescent Neuropsychopharmacology Network.

ECAPN in Enpr-EMA
The European Child & Adolescent Psychopharmacology Network (ECAPN) has been recognized as an Enpr-EMA Network.

Neuroscience-based Nomenclature Initiative

  • The Network worked on the Paediatric information of the NbN Initiative.

Recommended Publications

Authors   Year
 Title
 Journal and link to article
Moreno and Zuddas
 2019   Re-thinking treatment targets in child and adolescent psychiatry European Child & Adolescent Psychiatry
Persico et al.
 2015  Unmet needs in paediatric psychopharmacology: Present scenario and future perspectives  European Neuropsychopharmacology


Other applications (unsuccessful in being funded or not yet funded)

  • APPLE (Antipsychotics in the paediatric population: limiting exposure)
  • OPTI-MED (Establishing optimal ADHD medication strategies across Europe)
  • TAPS (Treatment of ADHD in Pre-Schoolers)
  • NIOTAS (Neuroimmune Interactions in Obsessive-Compulsive, Tourette’s, ADHD and Autism Spectrum Disorders)
  • METPSY (Understanding co-morbidity between cardio-metabolic disorders and severe psychiatric disorders through trans-generational, and early life course approach)
  • COBRA (COmputational approaches for Biomarker Identification in ADHD)